Bavarian Nordic A/S has announced the initiation of a Phase 3 clinical study for its chikungunya vaccine, CHIKV VLP, targeting children aged 2 to 11 years. The study, which is the first of its kind for this age group, aims to expand the approved use of the vaccine, currently available for individuals 12 years and older in the US, EU, and United Kingdom under the name VIMKUNYA®. This global, randomized, double-blind, placebo-controlled trial will assess the safety and immunogenicity of the vaccine in 720 children over a period of two years. Results from the study are expected in the first half of 2028.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.